Edward Matelan

Identification of pathway-selective estrogen receptor ligands that inhibit NF-κB transcriptional activity

Christopher C. Chadwick, Susan Chippari, Edward Matelan et al. · Proceedings of the National Academy of Sciences · 2005 · 135 citations · Full text

Medicine, Endocrinology, Pharmacology +17

Design and SAR of Novel Potassium Channel Openers Targeted for Urge Urinary Incontinence. 1. <i>N</i>-Cyanoguanidine Bioisosteres Possessing in Vivo Bladder Selectivity

John A. Butera, Madelene Antane, Schuyler Antane et al. · Journal of Medicinal Chemistry · 2000 · 79 citations

Pharmacy, Medicinal Chemistry, Pharmacology +17

Indazole-Based Liver X Receptor (LXR) Modulators with Maintained Atherosclerotic Lesion Reduction Activity but Diminished Stimulation of Hepatic Triglyceride Synthesis

Jay Wrobel, Robert J. Steffan, Susan Bowen et al. · Journal of Medicinal Chemistry · 2008 · 76 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +15

Synthesis and Activity of Substituted 4-(Indazol-3-yl)phenols as Pathway-Selective Estrogen Receptor Ligands Useful in the Treatment of Rheumatoid Arthritis

Robert J. Steffan, Edward Matelan, Mark A. Ashwell et al. · Journal of Medicinal Chemistry · 2004 · 70 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

3-(3-Aryloxyaryl)imidazo[1,2-a]pyridine sulfones as liver X receptor agonists

Robert R. Singhaus, Ronald C. Bernotas, Robert J. Steffan et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 60 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +6